Dr. Guadalupe Sabio joins the EMBO’s network of young researchers

Share
25 Oct 2017
About the CNIC
Research
  • La Dra. Guadalupe Sabio en su laboratorio.

Dr. Sabio leads a research group at the Carlos III National Cardiovascular Research Center (CNIC) whose main line of research are diseases related to obesity, like cardiovascular diseases, diabetes and liver cancer.


The researcher at the Carlos III National Cardiovascular Research Center (CNIC), Guadalupe Sabio, has joined EMBO’s network of young researchers, an organization of more than 1,700 leading researchers that promotes excellence in life sciences. Dr. Sabio is one of the 28 young researchers who join a network of another 47 young researchers and 417 researchers who were and who represent the best leaders of emerging groups in Bioscience research in Europe and other parts of the world.

"It is a pleasure to welcome these outstanding scientists to the EMBO community," says EMBO director Maria Leptin. "Among themselves they develop some of the most promising life sciences research that Europe can offer and we hope to support them in their professional and scientific initiatives."

Dr. Sabio directs a research group at the CNIC whose main line of research is the role of kinases activated by stress in the development of diseases related to obesity such as cardiovascular diseases, diabetes and liver cancer. She has a Degree in Veterinary Medicine from the University of Extremadura with Extraordinary Prize, in 2005 she obtained the European Doctorate from the Medical Research Council. She was accepted into Dr. Roger Davis’ group at the Howard Hughes Medical Institute of the University of Massachusetts for her research on protein kinases of stress. She has been recognized by the L'Oreal-Unesco Foundation for her study on obesity and its relation to liver cancer and diabetes.  Furthermore, she has received the Prince of Girona Prize in Science and Academy, and has recently been awarded one of the 50 Leonardo Scholarships to Researchers and Cultural Creators from the BBVA Foundation in the section of Basic Research for her project "Inhibition of P38gamma as a possible therapeutic target for liver cancer". For her work in favor of women's rights, she was also awarded the Star of the Community of Madrid prize and has been selected as one of the Top 100 Women Leaders in Spain in 2017.

EMBO is an organization of more than 1,700 leading researchers that promotes excellence in life science

The new Young Researchers come from 11 different countries. The selection of the Young Researcher EMBO Program is a recognition of exceptional research and scientific potential. Through the program, EMBO identifies and supports some of the best under 40 researchers who are in the process of establishing their own laboratory.

During their three-year term, the EMBO Young Investigators receive several benefits, including an amount of 15,000 euros and possible additional funds to support the establishment of their independent laboratories.